GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » Total Payout Ratio

Starpharma Holdings (Starpharma Holdings) Total Payout Ratio : 0.00 (As of May. 17, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Starpharma Holdings's current Total Payout Ratio is 0.00.


Starpharma Holdings Total Payout Ratio Historical Data

The historical data trend for Starpharma Holdings's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Total Payout Ratio Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.38 - -

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Starpharma Holdings's Total Payout Ratio

For the Biotechnology subindustry, Starpharma Holdings's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Total Payout Ratio falls into.



Starpharma Holdings Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Starpharma Holdings's Total Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -10.495
=0.00

Starpharma Holdings's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.692
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starpharma Holdings Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (Starpharma Holdings) Headlines

From GuruFocus

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma SPL7013 Nasal Spray for COVID-19 – Development Update

By Business Wire Business Wire 08-25-2020

Starpharma signs new DEP� agreement with MSD

By PRNewswire PRNewswire 08-10-2022

Starpharma Presentation Now Available for On-Demand Viewing

By PRNewswire PRNewswire 04-17-2018

Starpharma signs DEP� ADC Research Agreement with MSD

By PRNewswire PRNewswire 02-12-2021